Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Accounts Payables (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Accounts Payables for 15 consecutive years, with $674.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables rose 46.08% year-over-year to $674.3 million, compared with a TTM value of $674.3 million through Dec 2025, up 46.08%, and an annual FY2025 reading of $674.3 million, up 46.08% over the prior year.
  • Accounts Payables was $674.3 million for Q4 2025 at Neurocrine Biosciences, up from $584.3 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $674.3 million in Q4 2025 and bottomed at $171.9 million in Q1 2021.
  • Average Accounts Payables over 4 years is $408.8 million, with a median of $417.2 million recorded in 2024.
  • The sharpest move saw Accounts Payables fell 21.93% in 2024, then surged 48.79% in 2025.
  • Year by year, Accounts Payables stood at $205.9 million in 2021, then skyrocketed by 144.29% to $503.0 million in 2023, then fell by 8.23% to $461.6 million in 2024, then skyrocketed by 46.08% to $674.3 million in 2025.
  • Business Quant data shows Accounts Payables for NBIX at $674.3 million in Q4 2025, $584.3 million in Q3 2025, and $489.5 million in Q2 2025.